1/30/2023  4:59:45 PM Chg. +14.50 Volume Bid4:59:45 PM Ask4:59:45 PM Market Capitalization Dividend Y. P/E Ratio
959.60DKK +1.53% 725,320
Turnover: 266.77 mill.
-Bid Size: - -Ask Size: - 2735.41 bill.DKK 1.08% 46.25

Business description

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk markets its products in more than 180 countries.
 

Management board & Supervisory board

CEO
Lars Fruergaard Jørgensen
Management board
Karsten Munk Knudsen, Camilla Sylvest, Doug Langa, Henrik Wulff, Ludovic Helfgott, Marcus Schindler, Martin Horst Lange, Maziar Mike Doustdar, Monique Carter
Supervisory board
Helge Lund, Andreas Fibig, Anne Marie Kverneland, Henrik Poulsen, Jeppe Christiansen, Kasim Kutay, Laurence Debroux, Martin Mackay, Mette Bøjer Jensen, Stig Strøbæk, Sylvie Grégoire, Thomas Rantzau
 

Company data

Name: Novo Nordisk AS
Address: Novo Allé,DK-2880 Bagsværd
Phone: +45-4444-8888
Fax: -
E-mail: -
Internet: www.novonordisk.com/
Industry: Healthcare
Sector: Medical Products
Sub sector: Medical Supplies
End of financial year: 12/31
Free Float: 66.64%
IPO date: -

Investor relations

Name: Daniel Bohsen
IR phone: +45-3075-9085
IR Fax: -
IR e-mail: DABO@novonordisk.com

Main Shareholders

Freefloat
 
66.64%
Novo Holdings A/S
 
28.30%
BlackRock, Inc.
 
5.06%